If you'd put $30,000 in this ASX biotech stock 4 months ago, you'd have $140,000 now

This little Aussie battler has been killing it the past few years without much fanfare.

Is it fanciful imagining how rich one could be if only they had invested in a particular ASX stock?

I say no, because it keeps you motivated to keep researching and investing.

It also reminds you that diversification can not only reduce risk from losers, it allows spectacular winners to carry the whole portfolio upwards.

On that point, there is one small-cap stock that's been making waves in 2024.

In fact, it has almost tripled in share price so far this year.

Let's check out what's happening:

Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

Cast your mind back to spring

Perth biotech PharmAust Limited (ASX: PAA) may only have a market capitalisation of around $129 million, but not so long ago it was even smaller than that.

Let's go on a very short journey in the time machine — back to November.

At that time the PharmAust share price was hovering around 7 cents. In fact, it had been more or less at that mark for a good three years.

Hypothetically, let's imagine you bought $30,000 worth of shares then.

At the start of December, the company presented some favourable results from a study of its monopetal product. The solution aims to treat motor neurone disease (MND), which is known as Lou Gehrig's Disease in North America.

The market took notice and sent the stock shooting up.

But then just two weeks ago, more positive test results came out, that really put a rocket under the ASX stock.

The wash up is that the shares are 33 cents at the time of writing.

That $30,000 you invested just four months ago? That's now worth a cool $141,428.

How does that compare to a term deposit?

This biotech stock and a bunch of losers = win

Now, no one is expecting that you'll land this sort of winner every time.

But if you can manage one or two multi-baggers within a diversified portfolio, that's all you need to grow your wealth.

Check this out. 

Say, at the time you bought PharmAust shares, you also bought four other stocks for $30,000 each.

Then in the four months that PharmAust was going crazy, the other four were having a miserable time to dive 25% each.

Your overall portfolio would still be a stunning 54% up in just one-third of a year.

Good luck with your investments.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Senior man looking at his laptop and pondering something.
Healthcare Shares

Could Mesoblast shares rise over 100% in 12 months?

Bell Potter has given its view on this stock.

Read more »

Two scientists analysing results on a computer screen.
Healthcare Shares

$10,000 invested in Pro Medicus and CSL shares 3 years ago is now worth…

Was I better off investing $10,000 into Pro Medicus or CSL shares three years ago?

Read more »

A share market investment manager monitors share price movements on his mobile phone and laptop
Healthcare Shares

Fund managers are loading up on CSL shares. Here's why

CSL is attracting renewed interest from fundies.

Read more »

Happy businessman fist pumping while looking at a tablet.
Healthcare Shares

Mesoblast wins FDA nod for new Ryoncil potency test

Mesoblast gets FDA approval for a new Ryoncil potency assay, aiming to ensure quality and support product expansion.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces.
Healthcare Shares

Can CSL shares hit $200? 3 things that need to go right

CSL needs to prove its earnings engine is accelerating again, not merely stabilising.

Read more »

Group of doctors celebrate by pumping fists in the air.
Healthcare Shares

Telix Pharmaceuticals vs Ramsay Healthcare: Which ASX healthcare stock made investors richer in 2026?

And find out which has the strongest upside ahead.

Read more »

Buy and sell written on red dice on top of stock market charts.
Broker Notes

Up 98%: Are CSL shares now a buy, hold or sell?

A leading expert provides his forecast for CSL’s rocketing shares.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Broker Notes

What is this broker's view on Telix shares after yesterday's crash?

Here is the latest outlook from Bell Potter.

Read more »